JNJ's Consistent Payout Makes It a Top Pick for Down Markets
The company is facing a combination of slow revenue growth, unresolved legal battles over talc products, and looming drug price negotiations under new Medicare rules.
Johnson & Johnson (JNJ)
Market is closed
News
- 1 - 10
- Next >>
10 Undervalued Blue Chip Stocks Analysts Recommend for Smart Investing
Blue-chip stocks are great assets for investors looking for opportunities to grow their capital in the long term. Some call them steady oaks in the forest of finance.
Johnson & Johnson (JNJ) Announces Results for Phase 3b APEX Study
Johnson & Johnson (NYSE:JNJ) is one of the 10 Cheapest High-Quality Stocks to Buy According to Hedge Funds.
UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times
On June 12, UBS global equity strategist Andrew Garthwaite’s team pointed to Johnson & Johnson as one of the top cyclical picks, excluding financials, whose performance tends to move with the broader...
Retirement Stock Portfolio: 10 Safe Dividend Stocks to Buy Now
Dividend-paying stocks are often considered a dependable option for retirement portfolios.
10 Cheapest High Quality Stocks to Buy According to Hedge Funds
On June 4, Jurrien Timmer, director of Global Macro for Fidelity Management & Research Company released his commentary on the stock market outlook.
Judge Orders J&J Subsidiary to Pay $442 Million in Antitrust Lawsuit
Recently, a federal judge ruled that a Johnson & Johnson subsidiary must pay $442 million in damages after a jury concluded last month that the company had broken antitrust laws by withholding support...
Dow 20 Stocks List: Ranked By Hedge Fund Bullishness Index
The Dow Jones Industrial Average, often called the Dow Jones or just the Dow, is a stock market index that tracks 30 major publicly traded companies in the United States.
US FDA Votes in Favor of Benefit-Risk Profile of Johnson & Johnson's DARZALEX FASPRO
On May 20, Johnson & Johnson (NYSE:JNJ) announced that the FDA Oncologic Drugs Advisory Committee/ODAC voted 6-2 in favor of the benefit-risk profile of single-agent DARZALEX FASPRO (daratumumab and hyaluronidase...
Jim Cramer Notes That "People Are Staying Away From" Johnson & Johnson
“Or let's consider Johnson & Johnson, triple A balance sheet, many drugs in the pipeline, one of the best-run companies in America, if not the world, with perhaps the most billion-dollar franchises ...
- 1 - 10
- Next >>
Billionaire Hedge Funds
